MDMA
Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs
Costs of the therapy are estimated at up to $15,000.
The post Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs appeared first on Green…
A Republican lawmaker in Massachusetts introduced a bill that would both reschedule the psychedelic MDMA at the state level and cap possible therapy costs at $5,000 per session, though both developments are contingent on federal rescheduling of the drug.
The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), which estimated that the possible cost for MDMA treatments could reach as much as $13,000-$15,000 per patient, per visit.
Though it’s a nonprofit, MAPS has been lobbying heavily for federal psychedelics reform, and the Times reported in 2021 that many stakeholders expect the U.S. Food and Drug Administration to approve MDMA for therapeutic use as soon as this year.
In preparation for that possibility, MAPS launched a new corporate entity two years ago, The Times reported.
“Winning FDA approval would give MAPS at least six years of exclusivity to market its MDMA-guided treatments for PTSD, with a potential windfall of $750 million,” The Times reported in 2021, without much added context.
The exclusivity agreement is why Boldyga’s bill was celebrated by some psychedelics activists in Massachusetts, who alleged to Psychedelic Spotlight that MAPS is “lobbying for an exclusive monopoly over MDMA therapy,” as Bay Staters for Natural Medicine founder James Davies put it.
MAPS director Dr. Rick Doblin, however, told The Times in 2021 that any money made from MDMA therapy would be used to fund new research into psychedelic therapy, train new doctors, and lobby for further reforms.
“Our goal is mass mental health,” Doblin told The Times. “It’s not to amass a whole bunch of money.”
In addition, the Washington Post made clear in 2020 that the potential cost that activists are worried about – up to $15,000 per therapeutic session – is due to how expensive the treatments themselves remain – and because of obstacles getting such therapy covered by insurance.
That $15,000 price tag, The Post reported, included “42 hours of therapy, including three overnights,” as well as therapists working in “teams of two,” and found that clinicians are trying to bring costs down to make therapies more accessible for a wider patient base.
The post Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs appeared first on Green Market Report.
mdma psychedelic therapy ptsd psychedelics fund fda research-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness